Skip to main content

SJ901 Overview: Insights from the Principal Investigator

Giles Robinson, MD, discusses the rationale for using the MEK inhibitor mirdametinib to target brain tumors in children, adolescents and young adults with low-grade gliomas. 

 
 
Loading

A Study of MEK Inhibitor Mirdametinib for Low-Grade Glioma

 
 
Loading

Eligibility for SJ901